JP2010501585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501585A5 JP2010501585A5 JP2009525720A JP2009525720A JP2010501585A5 JP 2010501585 A5 JP2010501585 A5 JP 2010501585A5 JP 2009525720 A JP2009525720 A JP 2009525720A JP 2009525720 A JP2009525720 A JP 2009525720A JP 2010501585 A5 JP2010501585 A5 JP 2010501585A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyridine
- fluoro
- phenylamino
- furo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 17
- -1 2,2-dimethyl-1,3-dioxolanyl Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- GBJNZGDNTWILNB-UHFFFAOYSA-N furo[3,2-c]pyridine-2-carboxamide Chemical compound N1=CC=C2OC(C(=O)N)=CC2=C1 GBJNZGDNTWILNB-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- ZNGLPDOTLBLTIX-SECBINFHSA-N 7-chloro-n-[(2r)-2,3-dihydroxypropoxy]-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=C(Cl)C=NC=C2C=1NC1=CC=C(I)C=C1F ZNGLPDOTLBLTIX-SECBINFHSA-N 0.000 claims 2
- AREKJPKIPLDVQY-UHFFFAOYSA-N 7-fluoro-3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=C(F)C=NC=C2C=1NC1=CC=C(I)C=C1F AREKJPKIPLDVQY-UHFFFAOYSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- GOYLXWIEDLPDLQ-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yloxy)-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCC(CO)ONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F GOYLXWIEDLPDLQ-UHFFFAOYSA-N 0.000 claims 2
- MOKOPMFVODBALH-SNVBAGLBSA-N n-[(2r)-2,3-dihydroxypropoxy]-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F MOKOPMFVODBALH-SNVBAGLBSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000005976 1-phenylethyloxy group Chemical group 0.000 claims 1
- HIXYMKKKJVOWOY-MRVPVSSYSA-N 3-(2,5-difluoro-4-iodoanilino)-n-[(2r)-2,3-dihydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC(F)=C(I)C=C1F HIXYMKKKJVOWOY-MRVPVSSYSA-N 0.000 claims 1
- YOTPJQSYYZLQTK-SECBINFHSA-N 3-(2,6-difluoro-4-iodoanilino)-n-[(2r)-2,3-dihydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=C(F)C=C(I)C=C1F YOTPJQSYYZLQTK-SECBINFHSA-N 0.000 claims 1
- NSUHKSDBHFLPTJ-SNVBAGLBSA-N 3-(2-chloro-4-iodoanilino)-n-[(2r)-2,3-dihydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1Cl NSUHKSDBHFLPTJ-SNVBAGLBSA-N 0.000 claims 1
- ZSVBLZJTOHYBFS-UHFFFAOYSA-N 3-(2-fluoro-4-iodo-n-methylanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=CC=NC=C2C=1N(C)C1=CC=C(I)C=C1F ZSVBLZJTOHYBFS-UHFFFAOYSA-N 0.000 claims 1
- XCCBPYPWIAZDAS-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(1-hydroxypropan-2-yloxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCC(C)ONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F XCCBPYPWIAZDAS-UHFFFAOYSA-N 0.000 claims 1
- ZASFNBPGAMDLGQ-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(1-methylpiperidin-4-yl)oxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound C1CN(C)CCC1ONC(=O)C1=C(NC=2C(=CC(I)=CC=2)F)C2=CN=CC=C2O1 ZASFNBPGAMDLGQ-UHFFFAOYSA-N 0.000 claims 1
- YXSFFGDHEKCEFI-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(1h-imidazol-5-ylmethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOCC=2NC=NC=2)OC2=CC=NC=C12 YXSFFGDHEKCEFI-UHFFFAOYSA-N 0.000 claims 1
- BRHYIGCVKINWRY-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-4-methylfuro[3,2-c]pyridine-2-carboxamide Chemical compound C1=2C(C)=NC=CC=2OC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F BRHYIGCVKINWRY-UHFFFAOYSA-N 0.000 claims 1
- LFHVPNVFAIRFIX-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-7-methylfuro[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC=2C(C)=CN=CC=2C=1NC1=CC=C(I)C=C1F LFHVPNVFAIRFIX-UHFFFAOYSA-N 0.000 claims 1
- HJPVQFUUZVDHQC-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-7-phenylfuro[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=C(C=3C=CC=CC=3)C=NC=C2C=1NC1=CC=C(I)C=C1F HJPVQFUUZVDHQC-UHFFFAOYSA-N 0.000 claims 1
- OWQKOFHCOAAMTL-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-n-methylfuro[3,2-c]pyridine-2-carboxamide Chemical compound OCCON(C)C(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F OWQKOFHCOAAMTL-UHFFFAOYSA-N 0.000 claims 1
- LVHMCPRJISQGAK-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F LVHMCPRJISQGAK-UHFFFAOYSA-N 0.000 claims 1
- KQFHBRNOZGXYQF-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-hydroxypropoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound CC(O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F KQFHBRNOZGXYQF-UHFFFAOYSA-N 0.000 claims 1
- YMNVIHJYFYSIHE-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-methylpropoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound CC(C)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F YMNVIHJYFYSIHE-UHFFFAOYSA-N 0.000 claims 1
- BIQWLTRWWSVHFH-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-morpholin-4-ylethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOCCN2CCOCC2)OC2=CC=NC=C12 BIQWLTRWWSVHFH-UHFFFAOYSA-N 0.000 claims 1
- YHQVEEYIFZLAAL-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(2-piperidin-1-ylethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOCCN2CCCCC2)OC2=CC=NC=C12 YHQVEEYIFZLAAL-UHFFFAOYSA-N 0.000 claims 1
- CWSIFJGKWFWQAR-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-(oxan-4-yloxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOC2CCOCC2)OC2=CC=NC=C12 CWSIFJGKWFWQAR-UHFFFAOYSA-N 0.000 claims 1
- VTNSFKMQSHVVFX-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-[(2-methylpropan-2-yl)oxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound CC(C)(C)ONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F VTNSFKMQSHVVFX-UHFFFAOYSA-N 0.000 claims 1
- KQFHBRNOZGXYQF-SECBINFHSA-N 3-(2-fluoro-4-iodoanilino)-n-[(2r)-2-hydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound C[C@@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F KQFHBRNOZGXYQF-SECBINFHSA-N 0.000 claims 1
- KQFHBRNOZGXYQF-VIFPVBQESA-N 3-(2-fluoro-4-iodoanilino)-n-[(2s)-2-hydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound C[C@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F KQFHBRNOZGXYQF-VIFPVBQESA-N 0.000 claims 1
- AJZFZFIDJMYVGI-MERQFXBCSA-N 3-(2-fluoro-4-iodoanilino)-n-[(3s)-pyrrolidin-3-yl]oxyfuro[3,2-c]pyridine-2-carboxamide;formic acid Chemical compound OC=O.FC1=CC(I)=CC=C1NC1=C(C(=O)NO[C@@H]2CNCC2)OC2=CC=NC=C12 AJZFZFIDJMYVGI-MERQFXBCSA-N 0.000 claims 1
- RILXIUKJZTVWOR-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-[2-(2-oxopyrrolidin-1-yl)ethoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOCCN2C(CCC2)=O)OC2=CC=NC=C12 RILXIUKJZTVWOR-UHFFFAOYSA-N 0.000 claims 1
- JOSPHXYARVDBKV-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-[2-(methanesulfonamido)ethoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound CS(=O)(=O)NCCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F JOSPHXYARVDBKV-UHFFFAOYSA-N 0.000 claims 1
- GXPHNPWQZJWDIE-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-[2-(methylamino)ethoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound CNCCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F GXPHNPWQZJWDIE-UHFFFAOYSA-N 0.000 claims 1
- GPXSOWYDMXOJSA-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-hydroxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound ONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F GPXSOWYDMXOJSA-UHFFFAOYSA-N 0.000 claims 1
- NLSWTNSYKVDGOT-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-methoxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F NLSWTNSYKVDGOT-UHFFFAOYSA-N 0.000 claims 1
- YVUGLKUKJPAEAT-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-methylsulfonylfuro[3,2-c]pyridine-2-carboxamide Chemical compound CS(=O)(=O)NC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F YVUGLKUKJPAEAT-UHFFFAOYSA-N 0.000 claims 1
- IQXHJWQCHIFPOH-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-phenoxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOC=2C=CC=CC=2)OC2=CC=NC=C12 IQXHJWQCHIFPOH-UHFFFAOYSA-N 0.000 claims 1
- YYSYZXLKBHAFQP-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-phenylmethoxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOCC=2C=CC=CC=2)OC2=CC=NC=C12 YYSYZXLKBHAFQP-UHFFFAOYSA-N 0.000 claims 1
- PYVXSCSFCDZMET-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-piperidin-4-yloxyfuro[3,2-c]pyridine-2-carboxamide;formic acid Chemical compound OC=O.FC1=CC(I)=CC=C1NC1=C(C(=O)NOC2CCNCC2)OC2=CC=NC=C12 PYVXSCSFCDZMET-UHFFFAOYSA-N 0.000 claims 1
- WDYKHMRALAELNL-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-propan-2-yloxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound CC(C)ONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F WDYKHMRALAELNL-UHFFFAOYSA-N 0.000 claims 1
- GYCNBDSPAUCLMY-UHFFFAOYSA-N 3-(2-fluoro-4-iodoanilino)-n-propoxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound CCCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F GYCNBDSPAUCLMY-UHFFFAOYSA-N 0.000 claims 1
- IDPRSJFPZKEETI-UHFFFAOYSA-N 3-(2-fluoro-4-methoxyanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(OC)=CC=C1NC1=C(C(=O)NOCCO)OC2=CC=NC=C12 IDPRSJFPZKEETI-UHFFFAOYSA-N 0.000 claims 1
- XRJBBHQHSPVSSV-UHFFFAOYSA-N 3-(2-fluoro-4-methylsulfanylanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOCCO)OC2=CC=NC=C12 XRJBBHQHSPVSSV-UHFFFAOYSA-N 0.000 claims 1
- MBDVAIXTFKWSIQ-UHFFFAOYSA-N 3-(4-bromo-2-chloroanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(Br)C=C1Cl MBDVAIXTFKWSIQ-UHFFFAOYSA-N 0.000 claims 1
- KFCJJPYOSOKYOC-SNVBAGLBSA-N 3-(4-bromo-2-fluoroanilino)-n-[(2r)-2,3-dihydroxypropoxy]furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(Br)C=C1F KFCJJPYOSOKYOC-SNVBAGLBSA-N 0.000 claims 1
- CYMSZXYMQOWREV-UHFFFAOYSA-N 3-[2-fluoro-4-(hydroxymethyl)anilino]-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(CO)C=C1F CYMSZXYMQOWREV-UHFFFAOYSA-N 0.000 claims 1
- ZHAATOXXOFJKOI-UHFFFAOYSA-N 4-chloro-3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=CC=NC(Cl)=C2C=1NC1=CC=C(I)C=C1F ZHAATOXXOFJKOI-UHFFFAOYSA-N 0.000 claims 1
- DBCSLIDHWJMBTA-SECBINFHSA-N 7-bromo-n-[(2r)-2,3-dihydroxypropoxy]-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=C(Br)C=NC=C2C=1NC1=CC=C(I)C=C1F DBCSLIDHWJMBTA-SECBINFHSA-N 0.000 claims 1
- BLTCPZNAPZCEHZ-UHFFFAOYSA-N 7-chloro-3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=C(Cl)C=NC=C2C=1NC1=CC=C(I)C=C1F BLTCPZNAPZCEHZ-UHFFFAOYSA-N 0.000 claims 1
- MXTXYFYQDUYXJL-JTQLQIEISA-N 7-chloro-3-(2-fluoro-4-iodoanilino)-n-[(3s)-pyrrolidin-3-yl]oxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NO[C@@H]2CNCC2)OC2=C(Cl)C=NC=C12 MXTXYFYQDUYXJL-JTQLQIEISA-N 0.000 claims 1
- GHRBIPYIAHXFCH-UHFFFAOYSA-N 7-chloro-3-(2-fluoro-4-methylsulfanylanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOCCO)OC2=C(Cl)C=NC=C12 GHRBIPYIAHXFCH-UHFFFAOYSA-N 0.000 claims 1
- RZJMBERNOWZWPE-UHFFFAOYSA-N 7-cyano-3-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound OCCONC(=O)C=1OC2=C(C#N)C=NC=C2C=1NC1=CC=C(I)C=C1F RZJMBERNOWZWPE-UHFFFAOYSA-N 0.000 claims 1
- SJISFKLIAOHHHQ-UHFFFAOYSA-N 7-fluoro-3-(2-fluoro-4-iodoanilino)-n-(1-hydroxy-2-methylpropan-2-yl)oxyfuro[3,2-c]pyridine-2-carboxamide Chemical compound OCC(C)(C)ONC(=O)C=1OC2=C(F)C=NC=C2C=1NC1=CC=C(I)C=C1F SJISFKLIAOHHHQ-UHFFFAOYSA-N 0.000 claims 1
- KTCIDTVOVGOCMK-UHFFFAOYSA-N 7-fluoro-3-(2-fluoro-4-methylsulfanylanilino)-n-(2-hydroxyethoxy)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOCCO)OC2=C(F)C=NC=C12 KTCIDTVOVGOCMK-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- SEEBPOKQKKFAJK-UHFFFAOYSA-N C(=O)O.N1CC(CCC1)ONC(=O)C1=C(C=2C=NC=CC2O1)NC1=C(C=C(C=C1)I)F Chemical compound C(=O)O.N1CC(CCC1)ONC(=O)C1=C(C=2C=NC=CC2O1)NC1=C(C=C(C=C1)I)F SEEBPOKQKKFAJK-UHFFFAOYSA-N 0.000 claims 1
- ZEZHPEIEEFTILY-QMMMGPOBSA-N G-573 Chemical compound C[C@H](O)CONC(=O)C=1OC2=C(F)C=NC=C2C=1NC1=CC=C(I)C=C1F ZEZHPEIEEFTILY-QMMMGPOBSA-N 0.000 claims 1
- FZBPBLMUNZUMJG-UHFFFAOYSA-N N-(2-hydroxyethoxy)pyridine-2-carboxamide Chemical compound OCCONC(=O)c1ccccn1 FZBPBLMUNZUMJG-UHFFFAOYSA-N 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZMBOQMSDMSOZDL-LLVKDONJSA-N ethyl 2-[[(2r)-2,3-dihydroxypropoxy]carbamoyl]-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-7-carboxylate Chemical compound OC[C@@H](O)CONC(=O)C=1OC=2C(C(=O)OCC)=CN=CC=2C=1NC1=CC=C(I)C=C1F ZMBOQMSDMSOZDL-LLVKDONJSA-N 0.000 claims 1
- WWMNKLYZTHPRHY-OAHLLOKOSA-N ethyl 2-[[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxycarbamoyl]-3-(2-fluoro-4-trimethylsilylanilino)furo[3,2-c]pyridine-7-carboxylate Chemical compound C([C@@H]1OC(C)(C)OC1)ONC(=O)C=1OC=2C(C(=O)OCC)=CN=CC=2C=1NC1=CC=C([Si](C)(C)C)C=C1F WWMNKLYZTHPRHY-OAHLLOKOSA-N 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- UNYVYIUFNWQXAD-UHFFFAOYSA-N n-(2-aminoethoxy)-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound NCCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F UNYVYIUFNWQXAD-UHFFFAOYSA-N 0.000 claims 1
- FQZXTNYQLKBVCE-UHFFFAOYSA-N n-(2-ethenoxyethoxy)-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOCCOC=C)OC2=CC=NC=C12 FQZXTNYQLKBVCE-UHFFFAOYSA-N 0.000 claims 1
- LWZKXXOWKUQXSJ-UHFFFAOYSA-N n-(azetidin-3-yloxy)-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide;formic acid Chemical compound OC=O.FC1=CC(I)=CC=C1NC1=C(C(=O)NOC2CNC2)OC2=CC=NC=C12 LWZKXXOWKUQXSJ-UHFFFAOYSA-N 0.000 claims 1
- IQMBBDYZNBYJEJ-UHFFFAOYSA-N n-(cyclopropylmethoxy)-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound FC1=CC(I)=CC=C1NC1=C(C(=O)NOCC2CC2)OC2=CC=NC=C12 IQMBBDYZNBYJEJ-UHFFFAOYSA-N 0.000 claims 1
- HFYFOAKWXBVMDY-GFCCVEGCSA-N n-[(2r)-2,3-dihydroxypropoxy]-3-(4-ethynyl-2-fluoroanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(C#C)C=C1F HFYFOAKWXBVMDY-GFCCVEGCSA-N 0.000 claims 1
- KNOYKCKVZWXKDQ-GFCCVEGCSA-N n-[(2r)-2,3-dihydroxypropoxy]-3-(4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound OC[C@@H](O)CONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1 KNOYKCKVZWXKDQ-GFCCVEGCSA-N 0.000 claims 1
- DAHUPKFQCHIVJO-UHFFFAOYSA-N n-[2-(dimethylamino)ethoxy]-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound CN(C)CCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F DAHUPKFQCHIVJO-UHFFFAOYSA-N 0.000 claims 1
- WUNZFKVZZZPIKW-UHFFFAOYSA-N n-ethoxy-3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carboxamide Chemical compound CCONC(=O)C=1OC2=CC=NC=C2C=1NC1=CC=C(I)C=C1F WUNZFKVZZZPIKW-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- UELBUEVYUVDDJP-UHFFFAOYSA-N tert-butyl 4-[[3-(2-fluoro-4-iodoanilino)furo[3,2-c]pyridine-2-carbonyl]amino]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1ONC(=O)C1=C(NC=2C(=CC(I)=CC=2)F)C2=CN=CC=C2O1 UELBUEVYUVDDJP-UHFFFAOYSA-N 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83916106P | 2006-08-21 | 2006-08-21 | |
| US60/839,161 | 2006-08-21 | ||
| US87159106P | 2006-12-22 | 2006-12-22 | |
| US60/871,591 | 2006-12-22 | ||
| US91762307P | 2007-05-11 | 2007-05-11 | |
| US60/917,623 | 2007-05-11 | ||
| US94474107P | 2007-06-18 | 2007-06-18 | |
| US60/944,741 | 2007-06-18 | ||
| PCT/US2007/076344 WO2008024725A1 (en) | 2006-08-21 | 2007-08-20 | Aza-benzofuranyl compounds and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010501585A JP2010501585A (ja) | 2010-01-21 |
| JP2010501585A5 true JP2010501585A5 (enExample) | 2010-10-07 |
| JP5448818B2 JP5448818B2 (ja) | 2014-03-19 |
Family
ID=38925647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009525720A Expired - Fee Related JP5448818B2 (ja) | 2006-08-21 | 2007-08-20 | アザベンゾフラニル化合物および使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080085886A1 (enExample) |
| EP (1) | EP2069354B1 (enExample) |
| JP (1) | JP5448818B2 (enExample) |
| KR (1) | KR101428116B1 (enExample) |
| AR (1) | AR062468A1 (enExample) |
| AT (1) | ATE531720T1 (enExample) |
| AU (1) | AU2007286808B2 (enExample) |
| BR (1) | BRPI0714635A2 (enExample) |
| CA (1) | CA2660546A1 (enExample) |
| ES (1) | ES2376771T3 (enExample) |
| IL (1) | IL196956A (enExample) |
| MX (1) | MX2009001878A (enExample) |
| NO (1) | NO20091197L (enExample) |
| PE (1) | PE20080611A1 (enExample) |
| TW (1) | TWI411614B (enExample) |
| WO (1) | WO2008024725A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5349306B2 (ja) * | 2006-08-21 | 2013-11-20 | ジェネンテック， インコーポレイテッド | アザベンゾチオフェニル化合物および使用方法 |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| EP2085390A1 (en) | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| AU2010237801A1 (en) | 2009-04-14 | 2011-10-20 | Syngenta Participations Ag | Haloalkylsulfonanilide derivative |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| BR112012022801B8 (pt) | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| US20120157448A1 (en) | 2010-11-22 | 2012-06-21 | Adam Cook | Compounds for treating neurodegenerative diseases |
| WO2012163799A1 (en) | 2011-05-27 | 2012-12-06 | Bayer Intellectual Property Gmbh | Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides |
| AR087405A1 (es) * | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR20240110004A (ko) | 2014-03-14 | 2024-07-12 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| SG10202007111TA (en) | 2014-07-15 | 2020-09-29 | Genentech Inc | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| JP2017535528A (ja) | 2014-10-03 | 2017-11-30 | ノバルティス アーゲー | 組み合わせ治療 |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| CN108025051B (zh) | 2015-07-29 | 2021-12-24 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| HRP20220436T1 (hr) | 2015-11-03 | 2022-05-27 | Janssen Biotech, Inc. | Protutijela koja se specifično vežu na pd-1 i njihove uporabe |
| CN106883270B (zh) | 2015-11-26 | 2019-03-26 | 财团法人工业技术研究院 | 有机金属化合物、包含其的有机发光装置 |
| CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| KR102642411B1 (ko) | 2017-05-19 | 2024-02-28 | 엔플렉션 테라퓨틱스, 인코포레이티드 | 피부병 치료를 위한 피롤로피리딘-아닐린 화합물 |
| ES2913213T3 (es) | 2017-05-19 | 2022-06-01 | Nflection Therapeutics Inc | Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos |
| US11859252B2 (en) | 2017-09-08 | 2024-01-02 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| SG11202011633SA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Psma binding agents and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| JP7393808B2 (ja) | 2018-11-20 | 2023-12-07 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのナフチリジノン－アニリン化合物 |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| CN117551073A (zh) | 2018-11-20 | 2024-02-13 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病噻吩基苯胺化合物 |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| BR112021020532A2 (pt) | 2019-04-19 | 2022-03-15 | Janssen Biotech Inc | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 |
| AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CA3210246A1 (en) | 2021-01-28 | 2022-08-04 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
| IL304891A (en) | 2021-02-02 | 2023-10-01 | Servier Lab | Selective Protech BCL-XL compounds and methods of use |
| JP2024511373A (ja) | 2021-03-18 | 2024-03-13 | ノバルティス アーゲー | がんのためのバイオマーカーおよびその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| EP4525925A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| IL317103A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of MET inhibitor BCL-XL and methods of using them |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| AU2024234194A1 (en) | 2023-03-10 | 2025-08-07 | Novartis Ag | Panras inhibitor antibody-drug conjugates and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
| CN119285968B (zh) * | 2024-09-19 | 2025-06-20 | 黑龙江大学 | 一种光致变色稀土聚合物及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328920A (en) * | 1991-04-17 | 1994-07-12 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted (pyridinylamino)-indoles |
| US5214204A (en) * | 1991-07-19 | 1993-05-25 | Abbott Laboratories | Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity |
| EP0530537B1 (en) * | 1991-08-12 | 1997-01-08 | Takeda Chemical Industries, Ltd. | Condensed pyrimidine derivatives, their production and use as antitumor agents |
| CA2083891A1 (en) * | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
| JPH05345780A (ja) * | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
| US5852046A (en) * | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| US5350748A (en) * | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
| DE4425609A1 (de) * | 1994-07-20 | 1996-01-25 | Bayer Ag | Benzofuranyl- und Benzothienyloxazolidinone |
| FR2777886B1 (fr) * | 1998-04-27 | 2002-05-31 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6410562B1 (en) * | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| HUP0105113A3 (en) * | 1999-01-13 | 2004-11-29 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| FR2799756B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EE05450B1 (et) * | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
| DE10110750A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6653346B1 (en) * | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| PL401638A1 (pl) * | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
| AR038972A1 (es) * | 2002-03-13 | 2005-02-02 | Array Biopharma Inc | Derivados de bencimidazol n3 alquilado como inhibidores de mek |
| US20040009976A1 (en) * | 2002-04-30 | 2004-01-15 | Kumiko Takeuchi | Hypoglycemic imidazoline compounds |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| JP2005104838A (ja) * | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| DE10351436A1 (de) * | 2003-11-04 | 2005-06-09 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| ES2338060T3 (es) * | 2003-12-22 | 2010-05-03 | Basilea Pharmaceutica Ag | Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer. |
| US20090275570A1 (en) * | 2005-04-06 | 2009-11-05 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| AU2006284751A1 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| JP5349306B2 (ja) * | 2006-08-21 | 2013-11-20 | ジェネンテック， インコーポレイテッド | アザベンゾチオフェニル化合物および使用方法 |
| WO2008036196A2 (en) * | 2006-09-21 | 2008-03-27 | Wyeth | Indolylalkylpyridin-2-amines for the inhibition of beta-secretase |
-
2007
- 2007-08-20 CA CA002660546A patent/CA2660546A1/en not_active Abandoned
- 2007-08-20 BR BRPI0714635-3A patent/BRPI0714635A2/pt not_active IP Right Cessation
- 2007-08-20 KR KR1020097005786A patent/KR101428116B1/ko not_active Expired - Fee Related
- 2007-08-20 MX MX2009001878A patent/MX2009001878A/es active IP Right Grant
- 2007-08-20 AT AT07814272T patent/ATE531720T1/de active
- 2007-08-20 WO PCT/US2007/076344 patent/WO2008024725A1/en not_active Ceased
- 2007-08-20 EP EP07814272A patent/EP2069354B1/en active Active
- 2007-08-20 JP JP2009525720A patent/JP5448818B2/ja not_active Expired - Fee Related
- 2007-08-20 US US11/894,506 patent/US20080085886A1/en not_active Abandoned
- 2007-08-20 ES ES07814272T patent/ES2376771T3/es active Active
- 2007-08-20 AU AU2007286808A patent/AU2007286808B2/en not_active Ceased
- 2007-08-21 AR ARP070103712A patent/AR062468A1/es unknown
- 2007-08-21 TW TW096130982A patent/TWI411614B/zh not_active IP Right Cessation
- 2007-08-21 PE PE2007001135A patent/PE20080611A1/es not_active Application Discontinuation
-
2009
- 2009-02-09 IL IL196956A patent/IL196956A/en not_active IP Right Cessation
- 2009-03-20 NO NO20091197A patent/NO20091197L/no not_active Application Discontinuation